No insider purchase over the last 90 days. The latest, by 서영권, was filed 17 Nov 2022.
Rayence Co., Ltd.: what insiders have been doing
This page follows insider dealings at Rayence Co., Ltd. as filed with DART (FSS), a company from the Health Care sector. Over the twelve months to 1 November 2026, 1 filing were filed, from 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
With 1 filing in twelve months, the company is quieter than the median of 7 filings across the 2,655 companies we follow on the same exchange. Looking back to 2022, when coverage begins, insiders filed 1 purchase and 1 sale.
There has been no open-market purchase by an insider of Rayence Co., Ltd. for at least a year.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Rayence Co., Ltd.
레이언스 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions to enhance patient health.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
